about
Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling NetworksDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsA short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiformeTargeting p53 for Novel Anticancer Therapy.Dendrimers: synthesis, applications, and properties.Recombinant adenoviral vectors can induce expression of p73 via the E4-orf6/7 proteinChinese health biotech and the billion-patient market.Regulation of the target protein (transgene) expression in the adenovirus vector using agonists of toll-like receptors.Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm.Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.Use of suicide genes for cancer gene therapy: study of the different approaches.What is a cure and how do we get there?Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.Gene therapy of gynaecological diseases.Opportunities and barriers to establishing a cell therapy programme in South Africa.Functional lipids and lipoplexes for improved gene delivery.The effect and role of carbon atoms in poly(β-amino ester)s for DNA binding and gene delivery.Orphan drug development in China - Turning challenges into opportunities.Charge-reversal lipids, peptide-based lipids, and nucleoside-based lipids for gene delivery.Specifically targeted gene therapy for small-cell lung cancer.Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma.In vivo nucleic acid delivery with PEI and its derivatives: current status and perspectives.Therapeutic strategies for head and neck cancer based on p53 status.Poly(amidoamine) dendrimer complexes as a platform for gene delivery.The evolution of adenoviral vectors through genetic and chemical surface modifications.Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications.The state of gene therapy research in Africa, its significance and implications for the future.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.Oncolytic Immunotherapy for Treatment of Cancer.Gene delivery nanoparticles to modulate angiogenesis.An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames.Gene therapy in HIV-infected cells to decrease viral impact by using an alternative delivery method.Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors.Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies.Clinical trials and SCID row: the ethics of phase 1 trials in the developing world.Challenges and opportunities in bioanalytical support for gene therapy medicinal product development.Gene therapy: cursed or inching towards credibility?Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames.
P2860
Q26741086-7A09274C-8099-4041-B76C-6A935DC6B074Q26782083-712E9B95-5786-4C14-A11F-9267AFF4A611Q26849375-7DA7F907-FCBB-4780-BBCC-CDB362FC9C2FQ33655329-A3D6D9C2-8E51-4ADA-892B-7AE04B23BF1BQ33820501-78B9A0F3-57B8-4E2A-8DAC-233004F42CACQ34648372-3D5E9664-8F58-45AD-9F70-AE94A4B396D1Q34734228-179C25ED-0404-491D-8982-FAFA671034E0Q34750424-D81C1105-37A8-4A20-A93E-5CF5022899B3Q34893725-E0E96896-43DA-4DFA-8F2C-94B9A1189589Q35285768-E044509F-0DBA-493B-B0C6-331AEECCF8E8Q35753524-22929062-7FED-4306-B26A-13BA91FBD619Q35915700-A9061C1D-8DE9-44F8-B614-34B030FF981BQ35946185-9819A12F-B09C-43E6-84F3-5BD3B0713668Q36370715-4B8821BF-18CA-44F9-B400-115698B8C76CQ36922247-9E42C786-2B11-4F4D-A0B6-AFB2AAF9333EQ36998666-293A6062-CE18-41D7-8992-AA2A40F3A0ECQ37166374-970ED1CC-FFC4-43B4-8984-587D487F5066Q37338454-CD02287E-B60A-44FB-8E53-38BF7ECBF503Q37425316-439E5156-1962-44F9-B961-46333F50C36DQ37427230-CDFAC971-DF30-40D5-9614-2C49F9C7F328Q37449030-9CFA5822-1D20-40E2-A0FC-7E0156592F2EQ37818222-904F20FE-32AD-4825-B76A-A80312AF7E44Q37850449-20F7C200-FB1C-4D44-9F55-D850DEDD30CFQ38042630-337DC1AB-81C8-4FCF-BCBF-3A3F620DBE6CQ38156233-AE24C515-D5DB-4417-94BD-15293A339235Q38189250-17B42A99-895D-4DF3-AF67-0A052776A582Q38226307-38D01143-5415-44C8-938C-313727E3F49AQ38660339-BB35C698-C2DA-496A-96AA-55EA69C32FFBQ38848060-4BB528B3-1B64-44F5-9B61-38BB712FFF67Q38848223-1C67EBC9-079C-4A16-9891-662DF5EF5F93Q39027588-A4B95088-6634-4707-939A-DF5B665197A4Q39308911-757772FF-E22C-4544-A850-B0DC7354C01CQ39390082-406F1522-3CDE-41F6-98A9-D34BE158A3C4Q39711498-23500E21-DA05-430E-8DAA-00F55C8F7A0AQ40447916-3B49F08B-812B-4079-BB8B-7E2B930FBB9CQ42562347-F730DFDA-C99A-4FCA-B87C-2E79AAC1DCE4Q43978844-E09929A1-3949-4372-B605-12219014CC39Q45872061-4469EE0B-A85E-41F2-8C28-5AB6D0D7D558Q45883377-9A8671E8-7F7F-471D-A083-0490C0B5E78EQ46286420-AB812358-2B24-418E-A672-3FBC575B1203
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
China approves first gene therapy.
@en
China approves first gene therapy.
@nl
type
label
China approves first gene therapy.
@en
China approves first gene therapy.
@nl
prefLabel
China approves first gene therapy.
@en
China approves first gene therapy.
@nl
P2093
P356
P1433
P1476
China approves first gene therapy.
@en
P2093
Hepeng Jia
Keiko Kandachi
Sue Pearson
P2888
P356
10.1038/NBT0104-3
P577
2004-01-01T00:00:00Z